Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy
Brotons-Canto A (1), Gamazo C (1), Martín-Arbella N (1), Abdulkarim M (2), Gumbleton M (2), Quincoces G (3), Peñuelas I (3), Irache JM (4).
(1) NANO-VAC Research Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008, Pamplona, Spain.
(2) School of Pharmacy and Pharmaceutical Science, Cardiff University, Cardiff, UK.
(3) Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Spain.
(4) NANO-VAC Research Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008, Pamplona, Spain.
Peanut allergy is one of the most prevalent and severe of food allergies with no available cure.
The aim of this work was to evaluate the potential of an oral immunotherapy based on the use of a roasted peanut extract (PE) encapsulated in nanoparticles with immunoadjuvant properties.
For this, a polymer conjugate formed by the covalent binding of mannosamine to the copolymer of methylvinyl ether and maleic anhydride was firstly synthetized and characterized.
Then, the conjugate was used to prepare nanoparticles with an important capability to diffuse through the mucus layer and reach, in a large extent, the intestinal epithelium, including Peyer's patches.
Their immunotherapeutic potential was evaluated in a model of pre-sensitized CD1 mice to peanut. After completing therapy, mice underwent an intraperitoneal challenge with PE.
Nanoparticle-treatment was associated with both less serious anaphylaxis symptoms and higher survival rates than control, confirming the protective effect of this formulation against the challenge.
CITATION J Pharm Sci. 2019 Mar 5. pii: S0022-3549(19)30140-6. doi: 10.1016/j.xphs.2019.02.022.